Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

Registrieren

PVLA Palvella Therapeutics Inc

25,22

1,28 (5,35%)

Zuletzt aktualisiert: 20:13:09

Verzögert um 15 Minuten

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Palvella Therapeutics (NASDAQ:PVLA)
Historical Stock Chart
Von Feb 2025 bis Mär 2025

Click Here for more Palvella Therapeutics Charts.

Palvella Therapeutics (NASDAQ:PVLA)
Historical Stock Chart
Von Mär 2024 bis Mär 2025

Click Here for more Palvella Therapeutics Charts.

News Palvella Therapeutics Inc

Form 8-K - Current report
Dienstag 4 März 2025 (3 Tage vor) • Edgar (US Regulatory)

Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference
Dienstag 25 Februar 2025 (1 Woche vor) • GlobeNewswire Inc.

Form S-8 - Securities to be offered to employees in employee benefit plans
Dienstag 18 Februar 2025 (2 Wochen vor) • Edgar (US Regulatory)

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
Dienstag 11 Februar 2025 (4 Wochen vor) • Edgar (US Regulatory)

Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old
Montag 10 Februar 2025 (4 Wochen vor) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 7 Februar 2025 (4 Wochen vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 7 Februar 2025 (4 Wochen vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 7 Februar 2025 (4 Wochen vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 7 Februar 2025 (4 Wochen vor) • Edgar (US Regulatory)

Form 424B3 - Prospectus [Rule 424(b)(3)]
Freitag 17 Januar 2025 (2 Monate vor) • Edgar (US Regulatory)

Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies
Freitag 10 Januar 2025 (2 Monate vor) • GlobeNewswire Inc.

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Mittwoch 8 Januar 2025 (2 Monate vor) • Edgar (US Regulatory)

Weitere Palvella Therapeutics Inc News-Artikel

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen